395 related articles for article (PubMed ID: 28504613)
1. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
Kaneko MK; Nakamura T; Kunita A; Fukayama M; Abe S; Nishioka Y; Yamada S; Yanaka M; Saidoh N; Yoshida K; Fujii Y; Ogasawara S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):104-112. PubMed ID: 28504613
[TBL] [Abstract][Full Text] [Related]
2. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
Kato Y; Kunita A; Fukayama M; Abe S; Nishioka Y; Uchida H; Tahara H; Yamada S; Yanaka M; Nakamura T; Saidoh N; Yoshida K; Fujii Y; Honma R; Takagi M; Ogasawara S; Murata T; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):20-24. PubMed ID: 28234556
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.
Kaneko MK; Yamada S; Nakamura T; Abe S; Nishioka Y; Kunita A; Fukayama M; Fujii Y; Ogasawara S; Kato Y
Cancer Med; 2017 Apr; 6(4):768-777. PubMed ID: 28332312
[TBL] [Abstract][Full Text] [Related]
4. The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity.
Kato Y; Kunita A; Abe S; Ogasawara S; Fujii Y; Oki H; Fukayama M; Nishioka Y; Kaneko MK
Oncotarget; 2015 Nov; 6(34):36003-18. PubMed ID: 26416352
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Anti-Human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain.
Kaneko MK; Abe S; Ogasawara S; Fujii Y; Yamada S; Murata T; Uchida H; Tahara H; Nishioka Y; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):25-29. PubMed ID: 28157429
[TBL] [Abstract][Full Text] [Related]
6. Establishment of P38Bf, a Core-Fucose-Deficient Mouse-Canine Chimeric Antibody Against Dog Podoplanin.
Kato Y; Mizuno T; Yamada S; Nakamura T; Itai S; Yanaka M; Sano M; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2018 Nov; 37(5):218-223. PubMed ID: 30362926
[TBL] [Abstract][Full Text] [Related]
7. Development of Core-Fucose-Deficient Humanized and Chimeric Anti-Human Podoplanin Antibodies.
Kaneko MK; Ohishi T; Nakamura T; Inoue H; Takei J; Sano M; Asano T; Sayama Y; Hosono H; Suzuki H; Kawada M; Kato Y
Monoclon Antib Immunodiagn Immunother; 2020 Oct; 39(5):167-174. PubMed ID: 33085938
[TBL] [Abstract][Full Text] [Related]
8. Novel Monoclonal Antibody LpMab-17 Developed by CasMab Technology Distinguishes Human Podoplanin from Monkey Podoplanin.
Kato Y; Ogasawara S; Oki H; Honma R; Takagi M; Fujii Y; Nakamura T; Saidoh N; Kanno H; Umetsu M; Kamata S; Kubo H; Yamada M; Sawa Y; Morita K; Harada H; Suzuki H; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2016 Apr; 35(2):109-16. PubMed ID: 26937552
[TBL] [Abstract][Full Text] [Related]
9. A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin.
Kato Y; Kaneko MK
Sci Rep; 2014 Aug; 4():5924. PubMed ID: 25080943
[TBL] [Abstract][Full Text] [Related]
10. LpMab-23: A Cancer-Specific Monoclonal Antibody Against Human Podoplanin.
Yamada S; Ogasawara S; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Apr; 36(2):72-76. PubMed ID: 28387591
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of anti-glycopeptide monoclonal antibodies against human podoplanin, using glycan-deficient cell lines generated by CRISPR/Cas9 and TALEN.
Kaneko MK; Nakamura T; Honma R; Ogasawara S; Fujii Y; Abe S; Takagi M; Harada H; Suzuki H; Nishioka Y; Kato Y
Cancer Med; 2017 Feb; 6(2):382-396. PubMed ID: 28101903
[TBL] [Abstract][Full Text] [Related]
12. Establishment of Mouse Monoclonal Antibody LpMab-13 Against Human Podoplanin.
Ogasawara S; Kaneko MK; Honma R; Oki H; Fujii Y; Takagi M; Suzuki H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2016 Jun; 35(3):155-62. PubMed ID: 27328060
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
Abe S; Kaneko MK; Tsuchihashi Y; Izumi T; Ogasawara S; Okada N; Sato C; Tobiume M; Otsuka K; Miyamoto L; Tsuchiya K; Kawazoe K; Kato Y; Nishioka Y
Cancer Sci; 2016 Sep; 107(9):1198-205. PubMed ID: 27294401
[TBL] [Abstract][Full Text] [Related]
14. Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2.
Ogasawara S; Kaneko MK; Price JE; Kato Y
Hybridoma (Larchmt); 2008 Aug; 27(4):259-67. PubMed ID: 18707544
[TBL] [Abstract][Full Text] [Related]
15. Epitope Mapping of Monoclonal Antibody PMab-52 Against Cat Podoplanin.
Chang YW; Kaneko MK; Yamada S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2018 Apr; 37(2):95-99. PubMed ID: 29394131
[TBL] [Abstract][Full Text] [Related]
16. A defucosylated anti‑CD44 monoclonal antibody 5‑mG2a‑f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.
Takei J; Kaneko MK; Ohishi T; Hosono H; Nakamura T; Yanaka M; Sano M; Asano T; Sayama Y; Kawada M; Harada H; Kato Y
Oncol Rep; 2020 Nov; 44(5):1949-1960. PubMed ID: 33000243
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal Antibody LpMab-9 Recognizes O-glycosylated N-Terminus of Human Podoplanin.
Kaneko MK; Oki H; Hozumi Y; Liu X; Ogasawara S; Takagi M; Goto K; Kato Y
Monoclon Antib Immunodiagn Immunother; 2015 Oct; 34(5):310-7. PubMed ID: 26492618
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Monoclonal Antibody LpMab-7 Recognizing Non-PLAG Domain of Podoplanin.
Oki H; Kaneko MK; Ogasawara S; Tsujimoto Y; Liu X; Sugawara M; Takakubo Y; Takagi M; Kato Y
Monoclon Antib Immunodiagn Immunother; 2015 Jun; 34(3):174-80. PubMed ID: 26090595
[TBL] [Abstract][Full Text] [Related]
19. Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity.
Kaneko MK; Kunita A; Abe S; Tsujimoto Y; Fukayama M; Goto K; Sawa Y; Nishioka Y; Kato Y
Cancer Sci; 2012 Nov; 103(11):1913-9. PubMed ID: 22816430
[TBL] [Abstract][Full Text] [Related]
20. Characterization of monoclonal antibody LpMab-3 recognizing sialylated glycopeptide of podoplanin.
Oki H; Ogasawara S; Kaneko MK; Takagi M; Yamauchi M; Kato Y
Monoclon Antib Immunodiagn Immunother; 2015 Feb; 34(1):44-50. PubMed ID: 25723283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
